Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA against SENP2
- Development stage
- Preclinical
- Lead developer
- Academia Sinica
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
siRNA against SENP2 is a small interfering RNA designed to knock down the expression of SUMO-specific peptidase 2 (SENP2). SENP2 is a deconjugating enzyme involved in the SUMOylation pathway, which regulates protein activity post-translationally. Research conducted at Academia Sinica has identified a reduction of SENP2 in B cells from patients with systemic lupus erythematosus (SLE). Experimental knockdown of SENP2 using siRNA in human B cells leads to increased IgG antibody production, suggesting that SENP2 plays a role in restraining B-cell differentiation and antibody production. This siRNA is primarily used as a research tool to investigate the pathogenesis of SLE and the regulation of germinal center responses.
- Other names
- SENP2 siRNASENP-2 siRNASENP 2 siRNAsiRNA-SENP2siRNA-SENP-2siRNA-SENP 2
02
Targets
PRR (Pattern recognition receptors)SENP2 (Sentrin-specific protease 2)
Beyond the preview
Go deeper on siRNA against SENP2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA against SENP2.